Input Stories

President Trump has sent letters to biopharmaceutical manufacturers about imposing price controls on prescription drugs. 

• The letters direct biopharma manufacturers to “match the lowest price offered in other developed nations (known as the most-favored-nation, or MFN, price).”

The NAM says: “Manufacturers support the Trump administration’s commitment to lowering health care costs and ensuring American patients can access lifesaving medicines,” NAM President and CEO Jay Timmons said . “But European-style price controls will stifle innovation—undermining R&D and limiting future access to breakthrough treatments.”
 
A better way: “Manufacturers are working to reduce health care costs across the industry—for companies and for workers. That’s why the NAM supported expansions of telehealth coverage and increases to HSA amounts in H.R. 1, and it’s why policymakers should target the real drivers of cost—pharmacy benefit managers and abuse of the 340B program—instead of imposing mandates on innovators,” Timmons continued.

• “Manufacturers and manufacturing workers are facing rising health care costs because of underregulated middlemen like PBMs and the 340B program, both of which have increased prices for patients without producing a single treatment.”
• “Rather than punishing the innovators who develop lifesaving and life-changing medicines, policymakers should focus on the real inefficiencies and distortions in the system.”

The last word: “Manufacturers have long championed patient-first solutions that lower costs, strengthen American competitiveness and drive innovation. As we have underscored, there is a better way forward.”

• “Manufacturers remain committed to working with the administration and Congress on solutions that bring down prices while preserving our global leadership in innovation.”